Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension - Archive ouverte HAL Access content directly
Journal Articles Journal of Hepatology Year : 2022

Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension

Elisabetta Degasperi
Maria Paola Anolli
Sara Colonia Uceda Renteria
Dana Sambarino
  • Function : Author
Marta Borghi
  • Function : Author
Riccardo Perbellini
Floriana Facchetti
Alessandro Loglio
Sara Monico
Mirella Fraquelli
Andrea Costantino
Ferruccio Ceriotti
Pietro Lampertico
Not file

Dates and versions

hal-04013314 , version 1 (03-03-2023)

Identifiers

Cite

Elisabetta Degasperi, Maria Paola Anolli, Sara Colonia Uceda Renteria, Dana Sambarino, Marta Borghi, et al.. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. Journal of Hepatology, 2022, 77 (6), pp.1525-1531. ⟨10.1016/j.jhep.2022.07.016⟩. ⟨hal-04013314⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More